Click here to get full coverage on CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection - Yahoo Finance

CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection  Yahoo Finance

CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection - Yahoo Finance

Click here to get full coverage on CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency - TradingView — Track All Markets

CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency  TradingView — Track All Markets

CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency - TradingView — Track All Markets

Click here to get full coverage on CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon - simplywall.st

CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon  simplywall.st

CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon - simplywall.st

Click here to get full coverage on FDA highlights new brain monitor that may spot deadly hospital strokes sooner - Stock Titan

FDA highlights new brain monitor that may spot deadly hospital strokes sooner  Stock Titan

FDA highlights new brain monitor that may spot deadly hospital strokes sooner - Stock Titan

Click here to get full coverage on Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN) - The Globe and Mail

Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN)  The Globe and Mail

Analysts’ Top Healthcare Picks: Ceribell, Inc. (CBLL), Evommune, Inc. (EVMN) - The Globe and Mail

Click here to get full coverage on Insider Sale: Director at $CBLL Sells 25,000 Shares - Quiver Quantitative

Insider Sale: Director at $CBLL Sells 25,000 Shares  Quiver Quantitative

Insider Sale: Director at $CBLL Sells 25,000 Shares - Quiver Quantitative

Click here to get full coverage on Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat

Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock  MarketBeat

Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - MarketBeat

Click here to get full coverage on (CBLL) Movement as an Input in Quant Signal Sets - Stock Traders Daily

(CBLL) Movement as an Input in Quant Signal Sets  Stock Traders Daily

(CBLL) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Click here to get full coverage on CeriBell (CBLL) Q2 Revenue Jumps 38% - Nasdaq

CeriBell (CBLL) Q2 Revenue Jumps 38%  Nasdaq

CeriBell (CBLL) Q2 Revenue Jumps 38% - Nasdaq

Click here to get full coverage on CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution - Yahoo Finance

CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution  Yahoo Finance

CBLL Gets FDA Consent for One-of-a-Kind Delirium Monitoring Solution - Yahoo Finance

Click here to get full coverage on CBLL: 2026 growth will accelerate with new FDA clearances, VA expansion, and pediatric launches - TradingView — Track All Markets

CBLL: 2026 growth will accelerate with new FDA clearances, VA expansion, and pediatric launches  TradingView — Track All Markets

CBLL: 2026 growth will accelerate with new FDA clearances, VA expansion, and pediatric launches - TradingView — Track All Markets

Click here to get full coverage on CeriBell (CBLL) Revenue Growth Outpaces Market, But Persistent Losses Test Bullish Narrative - simplywall.st

CeriBell (CBLL) Revenue Growth Outpaces Market, But Persistent Losses Test Bullish Narrative  simplywall.st

CeriBell (CBLL) Revenue Growth Outpaces Market, But Persistent Losses Test Bullish Narrative - simplywall.st

Click here to get full coverage on New Analyst Forecast: $CBLL Given $30 Price Target - Quiver Quantitative

New Analyst Forecast: $CBLL Given $30 Price Target  Quiver Quantitative

New Analyst Forecast: $CBLL Given $30 Price Target - Quiver Quantitative

Click here to get full coverage on CeriBell (CBLL): Revenue Growth Forecast at 23.4% Drives High Valuation Despite Losses - Yahoo Finance

CeriBell (CBLL): Revenue Growth Forecast at 23.4% Drives High Valuation Despite Losses  Yahoo Finance

CeriBell (CBLL): Revenue Growth Forecast at 23.4% Drives High Valuation Despite Losses - Yahoo Finance

Click here to get full coverage on Analysts Have Been Trimming Their CeriBell, Inc. (NASDAQ:CBLL) Price Target After Its Latest Report - simplywall.st

Analysts Have Been Trimming Their CeriBell, Inc. (NASDAQ:CBLL) Price Target After Its Latest Report  simplywall.st

Analysts Have Been Trimming Their CeriBell, Inc. (NASDAQ:CBLL) Price Target After Its Latest Report - simplywall.st

Click here to get full coverage on CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates  Yahoo Finance

CeriBell, Inc. (CBLL) Reports Q3 Loss, Beats Revenue Estimates - Yahoo Finance

Click here to get full coverage on Ceribell director resigns to pursue other professional ventures - The Globe and Mail

Ceribell director resigns to pursue other professional ventures  The Globe and Mail

Ceribell director resigns to pursue other professional ventures - The Globe and Mail

Click here to get full coverage on Ceribell CEO Chao Xingjuan sells $470k in CBLL stock - Investing.com

Ceribell CEO Chao Xingjuan sells $470k in CBLL stock  Investing.com

Ceribell CEO Chao Xingjuan sells $470k in CBLL stock - Investing.com

Click here to get full coverage on J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT - Yahoo Finance

J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT  Yahoo Finance

J.P. Morgan Maintains a Buy Rating on CeriBell (CBLL) With a $21 PT - Yahoo Finance

Click here to get full coverage on Protara, Ceribell rise on FDA breakthrough designations - MSN

Protara, Ceribell rise on FDA breakthrough designations  MSN

Protara, Ceribell rise on FDA breakthrough designations - MSN

Click here to get full coverage on Precision Trading with CBLL Company (CBLL) Risk Zones - Stock Traders Daily

Precision Trading with CBLL Company (CBLL) Risk Zones  Stock Traders Daily

Precision Trading with CBLL Company (CBLL) Risk Zones - Stock Traders Daily

Click here to get full coverage on CeriBell (CBLL): Canaccord Genuity Raises Price Target to $30 | - GuruFocus

CeriBell (CBLL): Canaccord Genuity Raises Price Target to $30 |  GuruFocus

CeriBell (CBLL): Canaccord Genuity Raises Price Target to $30 | - GuruFocus

Click here to get full coverage on Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference  GlobeNewswire

Ceribell to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire

Click here to get full coverage on Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution - GlobeNewswire

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution  GlobeNewswire

Ceribell Receives FDA Breakthrough Device Designation for LVO Stroke Detection and Monitoring Solution - GlobeNewswire

Click here to get full coverage on Ceribell Reports Second Quarter 2025 Financial Results - Yahoo Finance

Ceribell Reports Second Quarter 2025 Financial Results  Yahoo Finance

Ceribell Reports Second Quarter 2025 Financial Results - Yahoo Finance

Click here to get full coverage on Understanding the Setup: (CBLL) and Scalable Risk - Stock Traders Daily

Understanding the Setup: (CBLL) and Scalable Risk  Stock Traders Daily

Understanding the Setup: (CBLL) and Scalable Risk - Stock Traders Daily

Click here to get full coverage on Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution - GlobeNewswire

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution  GlobeNewswire

Ceribell Receives FDA 510(k) Clearance for First-of-its-Kind Delirium Monitoring Solution - GlobeNewswire

Click here to get full coverage on Ceribell stock price target raised to $29 from $20 at TD Cowen on FDA clearance - Investing.com

Ceribell stock price target raised to $29 from $20 at TD Cowen on FDA clearance  Investing.com

Ceribell stock price target raised to $29 from $20 at TD Cowen on FDA clearance - Investing.com

Click here to get full coverage on Why CBLL stock is considered a top pick - Trade Entry Summary & AI Driven Stock Price Forecasts - Улправда

Why CBLL stock is considered a top pick - Trade Entry Summary & AI Driven Stock Price Forecasts  Улправда

Why CBLL stock is considered a top pick - Trade Entry Summary & AI Driven Stock Price Forecasts - Улправда

Click here to get full coverage on CeriBell: An EEG Concern Posting Impressive Growth (NASDAQ:CBLL) - Seeking Alpha

CeriBell: An EEG Concern Posting Impressive Growth (NASDAQ:CBLL)  Seeking Alpha

CeriBell: An EEG Concern Posting Impressive Growth (NASDAQ:CBLL) - Seeking Alpha

Click here to get full coverage on Ceribell’s Woo Raymond sells $136k in shares - Investing.com

Ceribell’s Woo Raymond sells $136k in shares  Investing.com

Ceribell’s Woo Raymond sells $136k in shares - Investing.com

Click here to get full coverage on Ceribell stock price target reiterated at $30 by BTIG, citing growth - Investing.com

Ceribell stock price target reiterated at $30 by BTIG, citing growth  Investing.com

Ceribell stock price target reiterated at $30 by BTIG, citing growth - Investing.com

Click here to get full coverage on Robertson of Ceribell sells $13k in shares - Investing.com

Robertson of Ceribell sells $13k in shares  Investing.com

Robertson of Ceribell sells $13k in shares - Investing.com

Click here to get full coverage on Ceribell extends leases for Sunnyvale offices through January 2028 - Investing.com

Ceribell extends leases for Sunnyvale offices through January 2028  Investing.com

Ceribell extends leases for Sunnyvale offices through January 2028 - Investing.com

Click here to get full coverage on Why CBLL stock is seen as undervalued - July 2025 Gainers & AI Driven Stock Movement Reports - Улправда

Why CBLL stock is seen as undervalued - July 2025 Gainers & AI Driven Stock Movement Reports  Улправда

Why CBLL stock is seen as undervalued - July 2025 Gainers & AI Driven Stock Movement Reports - Улправда

Click here to get full coverage on Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference  GlobeNewswire

Ceribell to Participate in the Piper Sandler 37th Annual Healthcare Conference - GlobeNewswire

Click here to get full coverage on Ceribell, Inc. SEC 10-Q Report - TradingView — Track All Markets

Ceribell, Inc. SEC 10-Q Report  TradingView — Track All Markets

Ceribell, Inc. SEC 10-Q Report - TradingView — Track All Markets

Click here to get full coverage on CeriBell's IPO Lockup Ends April 9 - Here's Why We're Shorting It Today (NASDAQ:CBLL) - Seeking Alpha

CeriBell's IPO Lockup Ends April 9 - Here's Why We're Shorting It Today (NASDAQ:CBLL)  Seeking Alpha

CeriBell's IPO Lockup Ends April 9 - Here's Why We're Shorting It Today (NASDAQ:CBLL) - Seeking Alpha

Click here to get full coverage on CeriBell stock climbs after FDA Breakthrough Device Designation By Investing.com - Investing.com Nigeria

CeriBell stock climbs after FDA Breakthrough Device Designation By Investing.com  Investing.com Nigeria

CeriBell stock climbs after FDA Breakthrough Device Designation By Investing.com - Investing.com Nigeria

Click here to get full coverage on Earnings call transcript: Ceribell Q3 2025 reveals 31% revenue growth - Investing.com

Earnings call transcript: Ceribell Q3 2025 reveals 31% revenue growth  Investing.com

Earnings call transcript: Ceribell Q3 2025 reveals 31% revenue growth - Investing.com

Click here to get full coverage on Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025 - Yahoo Finance

Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025  Yahoo Finance

Ceribell to Report Third Quarter 2025 Financial Results on November 4, 2025 - Yahoo Finance

Click here to get full coverage on Is CBLL stock positioned well for digital economy - Weekly Trading Summary & Real-Time Buy Zone Alerts - Улправда

Is CBLL stock positioned well for digital economy - Weekly Trading Summary & Real-Time Buy Zone Alerts  Улправда

Is CBLL stock positioned well for digital economy - Weekly Trading Summary & Real-Time Buy Zone Alerts - Улправда

Click here to get full coverage on Why CBLL stock is seen as undervalued - 2025 Technical Patterns & Weekly High Return Forecasts - Улправда

Why CBLL stock is seen as undervalued - 2025 Technical Patterns & Weekly High Return Forecasts  Улправда

Why CBLL stock is seen as undervalued - 2025 Technical Patterns & Weekly High Return Forecasts - Улправда

Click here to get full coverage on Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool - TipRanks

Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool  TipRanks

Ceribell Wins FDA Breakthrough Status for LVO Stroke Tool - TipRanks

Click here to get full coverage on Ceribell director Lucian Iancovici resigns from board and committees By Investing.com - Investing.com Australia

Ceribell director Lucian Iancovici resigns from board and committees By Investing.com  Investing.com Australia

Ceribell director Lucian Iancovici resigns from board and committees By Investing.com - Investing.com Australia

Click here to get full coverage on CeriBell: A Leader In AI-Powered Seizure Detection (NASDAQ:CBLL) - Seeking Alpha

CeriBell: A Leader In AI-Powered Seizure Detection (NASDAQ:CBLL)  Seeking Alpha

CeriBell: A Leader In AI-Powered Seizure Detection (NASDAQ:CBLL) - Seeking Alpha

Click here to get full coverage on Ceribell’s CFO Blumberg sells $756k in shares By Investing.com - Investing.com India

Ceribell’s CFO Blumberg sells $756k in shares By Investing.com  Investing.com India

Ceribell’s CFO Blumberg sells $756k in shares By Investing.com - Investing.com India

Click here to get full coverage on Ceribell Reports Third Quarter 2025 Financial Results - Sahm

Ceribell Reports Third Quarter 2025 Financial Results  Sahm

Ceribell Reports Third Quarter 2025 Financial Results - Sahm

Click here to get full coverage on CBLL Stock Price and Chart — NASDAQ:CBLL - TradingView — Track All Markets

CBLL Stock Price and Chart — NASDAQ:CBLL  TradingView — Track All Markets

CBLL Stock Price and Chart — NASDAQ:CBLL - TradingView — Track All Markets

Click here to get full coverage on Latham & Watkins Advises CeriBell on Upsized IPO - Latham & Watkins LLP

Latham & Watkins Advises CeriBell on Upsized IPO  Latham & Watkins LLP

Latham & Watkins Advises CeriBell on Upsized IPO - Latham & Watkins LLP

Click here to get full coverage on CBLL IPO News - Seizure diagnostic company CeriBell prices IPO at $17, the high end of the upwardly revised range - renaissancecapital.com

CBLL IPO News - Seizure diagnostic company CeriBell prices IPO at $17, the high end of the upwardly revised range  renaissancecapital.com

CBLL IPO News - Seizure diagnostic company CeriBell prices IPO at $17, the high end of the upwardly revised range - renaissancecapital.com

Click here to get full coverage on Contact - The Lethbridge Herald - News and Sports from around Lethbridge - FinancialContent

Contact - The Lethbridge Herald - News and Sports from around Lethbridge  FinancialContent

Contact - The Lethbridge Herald - News and Sports from around Lethbridge - FinancialContent

Click here to get full coverage on New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG - PR Newswire

New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG  PR Newswire

New Clinical Evidence Links Ceribell Point-of-Care EEG to Shorter Hospital Stays and Better Functional Outcomes Compared to Conventional EEG - PR Newswire

Click here to get full coverage on CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire

CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares  PR Newswire

CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - PR Newswire

Click here to get full coverage on CBLL IPO News - Seizure diagnostic company CeriBell sets terms for $101 million IPO - renaissancecapital.com

CBLL IPO News - Seizure diagnostic company CeriBell sets terms for $101 million IPO  renaissancecapital.com

CBLL IPO News - Seizure diagnostic company CeriBell sets terms for $101 million IPO - renaissancecapital.com

Click here to get full coverage on CeriBell Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView — Track All Markets

CeriBell Inc reports results for the quarter ended December 31 - Earnings Summary  TradingView — Track All Markets

CeriBell Inc reports results for the quarter ended December 31 - Earnings Summary - TradingView — Track All Markets

Click here to get full coverage on CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering - PR Newswire

CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering  PR Newswire

CeriBell, Inc. Announces Pricing of Upsized Initial Public Offering - PR Newswire

Click here to get full coverage on CBLL IPO News - Seizure diagnostic company Ceribell files for a $100 million IPO - renaissancecapital.com

CBLL IPO News - Seizure diagnostic company Ceribell files for a $100 million IPO  renaissancecapital.com

CBLL IPO News - Seizure diagnostic company Ceribell files for a $100 million IPO - renaissancecapital.com

Click here to get full coverage on Ceribell CEO Jane Chao explains why now was the time for its upsized IPO - Fierce Biotech

Ceribell CEO Jane Chao explains why now was the time for its upsized IPO  Fierce Biotech

Ceribell CEO Jane Chao explains why now was the time for its upsized IPO - Fierce Biotech

Click here to get full coverage on Ceribell’s stock soars 36% in trading debut after pricing IPO at top of range - MarketWatch

Ceribell’s stock soars 36% in trading debut after pricing IPO at top of range  MarketWatch

Ceribell’s stock soars 36% in trading debut after pricing IPO at top of range - MarketWatch

Click here to get full coverage on CeriBell IPO: Stock price soars as AI brain-monitoring headband maker debuts on Nasdaq - Fast Company

CeriBell IPO: Stock price soars as AI brain-monitoring headband maker debuts on Nasdaq  Fast Company

CeriBell IPO: Stock price soars as AI brain-monitoring headband maker debuts on Nasdaq - Fast Company

Click here to get full coverage on Ceribell Opens At $23.26, IPO Priced At $17 By Investing.com - Investing.com India

Ceribell Opens At $23.26, IPO Priced At $17 By Investing.com  Investing.com India

Ceribell Opens At $23.26, IPO Priced At $17 By Investing.com - Investing.com India

Click here to get full coverage on Analysts Set CeriBell, Inc. (NASDAQ:CBLL) Price Target at $24.67 - Defense World

Analysts Set CeriBell, Inc. (NASDAQ:CBLL) Price Target at $24.67  Defense World

Analysts Set CeriBell, Inc. (NASDAQ:CBLL) Price Target at $24.67 - Defense World

Click here to get full coverage on Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - Defense World

Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock  Defense World

Xingjuan Chao Sells 79,000 Shares of CeriBell (NASDAQ:CBLL) Stock - Defense World

Click here to get full coverage on CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 36,000 Shares of Stock - Defense World

CeriBell (NASDAQ:CBLL) CFO Scott Blumberg Sells 36,000 Shares of Stock  Defense World

CBLL

Price Chart

Key Statistics

Technicals

About CBLL

Latest News

CBLL Wins FDA Breakthrough Status for AI-Based LVO Stroke Detection - Yahoo Finance

CBLL: FDA-cleared AI neuromonitoring expands to pediatrics and delirium, driving growth and efficiency - TradingView — Track All Markets

CeriBell, Inc.'s (NASDAQ:CBLL) Shares May Have Run Too Fast Too Soon - simplywall.st

Advanced Charts

Top Gainers

Top Losers